Your Time Is Valuable. How Will You Spend Your Extra Hour? Passivation is now optional

Importance of the Topic

Charge variant analysis of monoclonal antibodies is critical for quality control, ensuring safety, efficacy and regulatory compliance in biotherapeutic production.

Objectives and Study Overview

This study compares the performance of Agilent Bio MAb PEEK columns versus Waters BioResolve SCX mAb columns for charge variant separations of a CHO-derived IgG1 monoclonal antibody under manufacturer-recommended conditions. Key metrics include reproducibility, resolution and operational efficiency.

Methodology

Samples were prepared at 5 mg/mL in standard buffers. Mobile phase A comprised 25 mM MES at pH 6.2, and mobile phase B was the same buffer supplemented with 0.5 M NaCl. A linear gradient from 10 to 40% B was applied at 25 °C. Prior to analysis, columns were equilibrated with ten column volumes of phase A followed by ten column volumes of phase B.

Instrumentation

Agilent 1290 Infinity II Bio LC System equipped with the 1290 Bio High-Speed Pump and controlled by Agilent OpenLab CDS software.

Main Results and Discussion

The Agilent Bio MAb PEEK column delivered consistent retention times and peak shapes across six replicate injections without any pre-passivation or sacrificial sample injections. In contrast, the Waters BioResolve SCX mAb column required six ten-minute priming runs (one hour total) with sacrificial sample to achieve stable performance. The polymeric PEEK column chemistry resisted metal-ion interactions and maintained high resolution in common buffer systems such as phosphate, MES and HEPES.

Benefits and Practical Applications

• Eliminates metal-induced sample loss through biocompatible flow paths.
• Removes need for lengthy system or column passivation, saving time and precious sample.
• Supports a wide range of buffer systems for flexible method development.
• Enhances throughput and reliability in QA/QC and biosimilar comparability workflows.

Future Trends and Applications

• Integration into automated, high-throughput LC platforms for large-scale screening.
• Broader adoption in multi-attribute method development for complex biologics.
• Expansion into other therapeutic classes and process monitoring applications.
• Development of next-generation bio-inert stationary phases for extreme pH and solvent conditions.

Conclusion

The Agilent Bio MAb PEEK column outperforms traditional stainless steel SCX columns by offering robust, reproducible charge variant separations without extensive passivation or sample sacrifice. Its bio-inert design and high stability support efficient and reliable biotherapeutic characterization workflows.